Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

COMPLETED

NCT04187976

Eosinophils Endotypes in Chronic Airway Inflammatory Diseases

Sponsor: University Hospital, Lille

View on ClinicalTrials.gov

Summary

Asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) are frequently described as unified airway inflammatory diseases. Both heavily impacts quality of life with substantial productivity loss. They share the same pathophysiologic pattern based upon proTh2 immune response with blood eosinophils recruitment. Eosinophils are the major actor of persistent mucosal inflammation by promoting their own survival, by attracting other inflammatory cells and by producing cytotoxic proteins involved in mucosal remodeling. Promising anti-Th2 therapeutic approaches (i.e.anti-IgE, anti-interleukin 5 (IL-5), anti-IL-4, anti-IL-13) are considered as effective alternative options to long-term corticosteroid treatment. Their advantage in recalcitrant CRSwNP is under consideration. Moreover, we still need to delineate the good responders to improve theirs indications. The objective is to assess blood eosinophil immunophenotypes in asthma or CRSwNP. Flow cytometric expression of activation markers on eosinophil membrane will be compared with a group of healthy subjects. Innovative data on eosinophil involvement in airway diseases will be obtained. The major outcome will be to depict patients' endotypes for a better selection of immunotherapies.

Official title: Peripheral Eosinophils Phenotypes in Airway Inflammatory Diseases: Towards Proper Clustering and Therapeutic Targeting

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

Start Date

2020-03-03

Completion Date

2023-10-30

Last Updated

2026-05-14

Healthy Volunteers

Conditions

Eosinophilic Asthma Chronic Sinusitis Eosinophilic Rhinitis

Inclusion Criteria: For all groups: * Social insured patient * Patient willing to comply with all procedures of the study and its duration * Provision of signed and dated informed consent form prior to any study specific procedure For Group 1: \- Patients with moderate to severe uncontrolled asthma, confirmed by relevant clinical symptoms and proven variable airway obstruction, and assessed by an expert pulmonologist according to spirometry criteria (absolute and weighed Forced Expiratory Volume (FEV) and Forced Vital Capacity (FVC) before and after 2 test),(see CRF for details). Uncontrolled asthma will be defined by an ACQ score ≥ 1.5. or acute exacerbation For Groups 2 and 3: * Patients with medically refractory bilateral sino-nasal polyposis requiring sinus surgery, according to an expert rhinologist. CRSwNP diagnosis is based on the presence of bilateral nasal polyps from both side of middle turbinates on nasoendoscopy and bilateral sinus opacification on CT scan. Briefly, CRSwNP is considered as refractory when symptoms are still not controlled after 3 courses of oral corticosteroid and double dose of nasal corticosteroid during the last 12 months * Patients with both uncontrolled asthma and recalcitrant CRSwNP with or without concomitant aspirin-exacerbated respiratory disease (AERD) (group 3) For Group 4: \- Healthy subjects without any airway disease or any atopic status, as assessed by a questionnaire and a medical examination Exclusion Criteria: For all groups: * Patients with any other form of secondary CRSwNP (eg, cystic fibrosis, primary ciliary dyskinesia). * Patients with any form of secondary severe asthma (eg (non)eosinophilic granulomatosis with polyangiitis, allergic bronchopulmonary aspergillosis) * Patients taking or having taken systemic corticosteroid, leukotriene receptor antagonist, theophylline or long-term macrolide therapy within 1 month prior to sample collections, anti-immunoglobulin E therapy (omalizumab) anti-IL-5/5R or anti IL-4R/anti-IL13 therapies within 6 months before inclusion * Patients followed up for another inflammatory or auto-immune disease * Previous allogeneic bone marrow transplant * Patients with ongoing sub-cutaneous or sub-lingual anti-allergenic immunotherapies * Patients with active smoking or history of smoking \> 10 packages-year for asthma patients * Pregnant, breastfeeding, or lactating women * Non-coverage by the social security insurance * Patient unable to receive informed information * Refusal to sign the consent form * Unwillingness or inability to follow the study procedures, in the opinion of the investigator * Person deprived of the liberty * Person benefiting from a system of legal protection (guardianship…)

Locations (1)

CHU Lille

Lille, France